Torrey Pines Investment
Venture capitalSan Diego · Seed–Series A · 7 people tracked
Investment thesis
Torrey Pines Investment focuses on the life-sciences sector, backing biopharma and diagnostics accelerators and investing in early development-stage assets from pharma and biotech partners across CNS, oncology, and virology areas. The firm aims to advance these assets toward success through pharma partnering and M&A. It supports portfolio companies with both product and corporate development, drawing on expertise in drug discovery — including non-clinical and clinical studies, manufacturing and quality, and regulatory affairs — to help them achieve growth, build value, and realize wealth.
Source: firm website, verified Aug 3, 2026.
Team · 7 people
from the firm's website & public directories
What they invest in
from 7 of 10 portfolio companiesBiotech ×7Healthtech ×3Deep Tech ×2
HQs:United States×3Finland×1
Investments · 10 tracked
founders shown can be your intro pathBiotechPhiladelphia, US
Alex Levit(Executive Officer)Linda Beth West(Director)Martin Albert Lehr(Executive Officer, Director)Richard Jay Berman(Director)Philip Kantoff(Director)Jennifer Minai-Azary(Executive Officer)
i2020 Accelerator (T123 LLC) is a drug discovery accelerator that de-risks early-stage science and advances drug discovery platforms toward lead and clinical candidate stage within roughly two years, working across therapeutic areas such as oncology, immunology, and infectious diseases.
BiotechDeep TechHealthtech
Contract research organization specializing in CNS preclinical efficacy and neurotoxicity evaluations using its patented Enhanced Spine Profiling (ESP) technology.
Clinical-stage drug-device company developing pegloprastide (AVB-620) for real-time surgical margin detection in cancer surgery.
Chromis Thera is a pharmaceutical company developing drugs to treat viral diseases, including a Favipiravir-based treatment for COVID-19 and therapies targeting hepatitis B virus (HBV).
BiotechHealthtech
Oncology company developing targeted and immuno-oncology therapeutics; lead candidate DKN-01 targets the DKK1 protein.
BiotechCambridge, US
John Littlechild(Director)Thomas Dietz(Director)Joseph Loscalzo(Director)Nissim Mashiach(Director)James Cavanaugh(Director)Douglas Onsi(Chief Financial Officer)
Leap Therapeutics (Nasdaq: LPTX) develops targeted and immuno-oncology antibody therapeutics for cancer patients, with its lead candidate DKN-01 (sirexatamab), an anti-DKK1 monoclonal antibody, in clinical development for esophagogastric, gynecologic, and colorectal cancers.
BiotechHealthtech
Polku Therapeutics is a preclinical CNS drug discovery company developing small-molecule therapies that modulate the PREP–PP2A axis to target tau aggregation and neuroinflammation in neurodegenerative diseases.
BiotechDeep Tech
Simon(Chief Executive Officer)Sebastian(Chief Operating Officer)Timo(Scientific Co-founder)Erik(Scientific Co-founder)
Biotechnology company enhancing vaccine performance with its HD-MAP high-density microarray skin-delivery platform, targeting infectious disease and oncology.
Exits · 1
IPOs and acquisitions across the tracked portfolioContext TherapeuticsNASDAQ: CNTX
Frequently asked questions
- What stage does Torrey Pines Investment invest at?
- Torrey Pines Investment invests at the Seed, Series A stages.
- What sectors does Torrey Pines Investment focus on?
- Torrey Pines Investment focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Torrey Pines Investment located?
- Torrey Pines Investment is headquartered in San Diego, US.
- Does Torrey Pines Investment lead rounds?
- Yes, Torrey Pines Investment leads investment rounds.
Images
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.
B Capital Group is a global venture capital firm that backs founders from early to late stage, with dedicated stage-based funds and a portfolio spanning technology, healthcare, and energy and resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
DCVC (Data Collective) is a venture capital firm that backs founders building companies which apply technology to major challenges across areas such as energy, biotech, agriculture, and machine learning.
Future Positive Capital's portfolio page showcasing companies across health, climate, and deeptech sectors.